Description Module
The Description Module contains narrative descriptions of the clinical trial, including a brief summary and detailed description. These descriptions provide important information about the study's purpose, methodology, and key details in language accessible to both researchers and the general public.
Description Module path is as follows:
Study -> Protocol Section -> Description Module
Description Module
Ignite Creation Date:
2025-12-24 @ 7:34 PM
Ignite Modification Date:
2025-12-24 @ 7:34 PM
NCT ID:
NCT07219303
Brief Summary:
The goal of this clinical trial is to evaluate if adaptive stereotactic body radiation therapy (SBRT) is a safe and effective way to treat prostate cancer in adults. It will assess the safety profile of adaptive SBRT over time.
The main questions this trial aims to answer are:
* What is highest dose of adaptive SBRT without causing serious side effects?
* Can adaptive SBRT more precisely targeting the prostate while reducing radiation exposure to nearby organs?
* What side effects do participants experience during treatment, right after treatment, and over the five years post-treatment?
* Can adaptive SBRT reduce urination-related side effects and support quality of life during and after treatment?
Participants will:
* Receive adaptive SBRT treatment every other day, for a total of 5 treatment sessions (called fractions). The full course of treatment typically takes 2 to 3 weeks.
* Have a follow-up phone call about 6 weeks after treatment to check on side effects and overall wellbeing.
* Visit the clinic for check-ups and tests:
* At 90 days (about 3 months) after treatment
* Then every 3 months for the first year
* Then every 6 months after that
Study:
NCT07219303
Study Brief:
Protocol Section:
NCT07219303